izentrop wrote:COVID-1273 mRNA-19 vaccine: encouraging preliminary results from a phase I trial in 45 participants
https://quoidansmonassiette.fr/vaccin-c ... -phase-i-1The amount of IgG antibody (ImmunoGlobulin G) increased rapidly after the 1st vaccination with seroconversion in all participants on D15. There is a dose response effect.
In conclusion, the mRNA-1273 vaccine was immunogenic, inducing antibody and lymphocyte responses. The durability of the immune response has not been evaluated. The follow-up was 57 days in this publication (the follow-up will last 1 year after the 2nd vaccination).
However, you have to keep in mind that this is not a phase III clinical trial where participants are confronted in real conditions with SARS-CoV-2.
A phase 2 trial of mRNA-1273 in 600 healthy adults, evaluating doses of 50 μg and 100 μg, is underway (NCT04405076). A phase 3 efficacy trial is expected to evaluate a dose of 100 μg and is expected to begin in the summer of 2020. The US NIH (American National Institutes of Health) is supporting this clinical trial.
The “for”:
- detection via IgG antibodies (ImmunoGlobulin G), that's what you have to do, of course!
- the test was undertaken quickly.
Against the"
- 45 patients is largely insufficient! (eh-eh-eh ...)
- If a double-blind randomized study with 2 different concentrations, then each group is 11 people (I'm laughing!)
- If not, I laugh even more
- Nothing proves to me that in 4 to 6 months immunity will still work: “durability of immune response” (rere-eh-eh-eh ...)
- the guys got an order for a vaccine worth 8 billion euros, but they are testing only 45 guinea pigs! Huge !
(ha whew, we shouldn't test too much in case the virus flops, right?)
______________
PS: [“Heavy” mode: OFF] bah woué, we can also ... and it's not even exaggerated